BioPharmCatalyst@BPharmCatalyst
$HCWB reported a profitable first quarter of 2026, swinging to a net income of $3.47 million on $6.54 million in revenue, driven primarily by a $6.5 million nonrefundable upfront license fee from Trimmune. Supported by reduced operating expenses, the company highlighted key upcoming pipeline milestones, including Phase 1 data for HCW9302 in alopecia areata, expected in the fourth quarter of 2026, and the completion of IND-enabling work for HCW11-018b, targeted for the first half of 2027. Additionally, the company announced preclinical findings from its ongoing IND-enabling studies showing that its pembrolizumab-based fusion immunotherapeutic, HCW11-040, effectively prevented bronchopulmonary dysplasia (BPD) in a highly stringent animal model.
$HCWB $DARE $PPBT $GDTC $KLRS $AARD $LFWD $AERO $WOK $CLDI
See More Pre-market Movers
biopharmcatalyst.com/news/2026/hcw-…